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In an mRNA proﬁling screen performed to unveil novel mechanisms of leukemogenesis, we found that
the sentrin-speciﬁc protease 5 (SENP5) was signiﬁcantly repressed in clinical acute myeloid leukemia
when compared to healthy neutrophil samples. SENP5 is an enzyme that targets and cleaves small
ubiquitin-like modiﬁer (SUMO) residues from SUMOylated proteins. Further investigation with AML
neutrophil differentiation cell models showed increased SENP5 expression upon induction of differ-
entiation; in contrast, knocking down SENP5 resulted in signiﬁcantly attenuated neutrophil differentia-
tion. Our results support a new role of SENP5 in AML pathology, and in particular in the neutrophil
differentiation of myeloid leukemic cells.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Acute myeloid leukemia (AML) is the most common acute
leukemia in adults, with an incidence of 2.5 cases per 100,000
persons worldwide per year [1]. In AML a variety of genetic
aberrations, often relevant for cellular differentiation and cell survi-
val, lead to an accumulation of clonal, myeloid precursor cells in the
bone marrow and ultimately to failure of hematopoiesis [1]. Acute
promyelocytic leukemia (APL) is characterized by the PML-RARA
onco-fusion protein that initiates the disease by promoting a block in
myeloid differentiation and proliferation of the promyelocytic blasts
[2]. APL patients are currently treated with all-trans retinoic acid
(ATRA), which directly targets PML-RARA for degradation by acti-
vated caspases and the proteasome, thereby overcoming the differ-
entiation block [2]. Interestingly, PML-RARA degradation by arsenic
trioxide is triggered by sumoylation [3–5].
In an attempt to identify novel genes with a role in AML dif-
ferentiation, we performed gene expression proﬁling experiments foc-
using on genes involved in cellular proliferation and survival including
the sentrin-speciﬁc protease 5 (SENP5). SENP proteins are a family of
proteins that remove small ubiquitin-like modiﬁers (SUMO's) from
SUMOylated proteins, thereby altering protein function [6]. Recently,
sumoylation was associated with resistance towards chemotherapy in
AML [7], but a possible role in differentiation has not been studied yet.
We found that SENP5 is downregulated in primary AML patient
samples and its expression is induced upon ATRA-mediated neutrophil
differentiation of primary APL cells and different AML cell lines.
Moreover, impairing SENP5 expression in APL cells decreased ATRA-
induced granulocytic differentiation.
2. Materials and methods
2.1. Patient samples
Fresh leukemic blast cells from untreated AML patients at diagnosis
were obtained at the Inselspital Bern (Switzerland) and mononuclear
cells were separated using a Ficoll gradient (Lymphoprep™, Axon Lab
AG, Switzerland). The isolation of primary neutrophils (purity 495%)
was performed by separating blood cells from healthy donors using
PolymorphprepTM (Axon Lab AG, Switzerland). CD34þ cells from cord
blood or bone marrow as well as macrophages were isolated as
described [8]. Protocols and the use of human samples acquired in
Bern were approved by the Cantonal Ethical Committee.
2.2. Cell lines, differentiation and cell survival
Neutrophil differentiation was performed as described [9]. Success-
ful neutrophil differentiation was assessed by increased CEBPE mRNA
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expression and by surface CD11b expression (#21279114 Immunotools,
Friesoythe, Germany) using ﬂow cytometric analysis. Cell viability upon
ATRA treatment was measured using an alamarBlues assay
(Invitrogen).
2.3. Real-time quantitative reverse transcription-PCR (qPCR)
Total RNAwas extracted using the RNeasy Mini Kit according to the
manufacturer's protocol (Qiagen). Total RNA was reverse transcribed
using random primers (Roche Diagnostics) and M-MLV reverse
transcriptase (Promega). PCR and ﬂuorescence detection were per-
formed using the ABI PRISMs 7700 Sequence Detection System
(Applied Biosystems). TaqMan low density arrays were performed
and analyzed as described [9]. For quantiﬁcation of SENP5 and CEBPE
the Taqmans (Applied Bioscience) Gene Expression Assays
Hs00381410_m1 and Hs00357657_m1 were used, respectively. HMBS
primers and probes have been described [9]. N-fold changes were
calculated using the ΔΔCt method of relative quantiﬁcation. Data
represent the mean7s.e.m. of at least triplicate experiments.
2.4. Lentivirus production and transduction
Lentiviral vectors expressing shRNAs targeting SENP5 were pur-
chased from Sigma-Aldrich (SHCLNG-NM_152699.2-300s1c1 and
SHCLNG-NM_ 152699.2-1325s1c1). Lentivirus production, transduc-
tion and selection of cell populations were done as described [9].
2.5. Statistical analysis
Nonparametric Mann–Whitney U tests were applied to compare
the difference between 2 groups using the program Prism (Graph-
Pad). p values less than 0.05 were considered to be statistically
signiﬁcant.
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Fig. 1. Inhibition of SENP5 expression in clinical AML patient samples. SENP5mRNA
expression was determined in primary AML samples (n¼83), including FAB M0-M5
AML subtypes, as well as AML with genetic aberrations such as CEBPA, NPM or
FLT3-ITD mutations, t(8;21), t(15;17) and inv (16); CD34þ progenitor cells obtained
from peripheral blood of multiple myeloma patients (n¼3) and cord blood (n¼1);
healthy granulocytes (n¼6) and macrophages (n¼7). Mann–Whitney-U tests:
npo0.05, nnpo0.01, nnnpo0.001.
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Fig. 2. Induction of SENP5 expression upon neutrophil differentiation of AML cells. (A, upper panels) SENP5 qPCR analysis in NB4, NB4-R2, HT93 and HL60 cells. Total mRNA
was extracted at day 4 and day 6 after differentiation with 1 μM ATRA. Values were normalized to the expression of the housekeeping gene HMBS and are shown as n-fold
mRNA expression to the levels of the control at day 4 of treatment with ATRA. (A, lower panels) CEBPE qPCR analysis in NB4, NB4-R2, HT93 and HL60 cells treated and
analyzed as in (A). Induction of SENP5message in two patients with newly diagnosed APL t(15;17), treated with orally administered ATRA at a dosage of 45 mg/m2 daily. Total
RNA was extracted from blast cells isolated using a Ficoll gradient and expression levels of SENP5 were assessed by qPCR. Values were normalized to HMBS and day 0 as the
experimental starting point. Mann–Whitney-U tests: npo0.05, nnnpo0.001.
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3. Results and discussion
3.1. Low SENP5 expression in primary AML blast cells
We ﬁrst investigated whether SENP5 may be involved in AML
pathology by quantifying SENP5 mRNA expression in 82 of 83
primary AML patient samples and comparing expression levels to
healthy granulocytes, macrophages or CD34þ progenitor cell sam-
ples (Fig. 1). The analysis of SENP5 mRNA levels in granulocytes
(mean ΔCt¼3.9) or macrophages (mean ΔCt¼0.32) from healthy
donors, or in CD34þ progenitor cells (mean ΔCt¼1.24) showed
signiﬁcantly higher SENP5 message expression in granulocytes as
compared to the other hematopoietic cells (po0.01). Most impor-
tantly, the SENP5 expression in AML cells was downregulated
approximately 6-fold (mean ΔCt¼0.61), as compared to
granulocytes (po0.001). These results indicate that higher SENP5
expression is associated with the granulocyte lineage, whereas
immature CD34þ progenitors, macrophages, and AML blast cells
display lower SENP5 message levels.
3.2. SENP5 expression is induced during neutrophil differentiation of
AML cells
Intrigued by the low SENP5 expression in immature AML blast
cells as compared to healthy mature neutrophils, we decided to
quantify SENP5 mRNA expression during ATRA induced neutrophil
differentiation of three in vitro models, namely NB4 and HT93 APL
as well as HL60 AML-M2 cells. First, we observed a signiﬁcant 2.3-
and 3.7-fold increase of SENP5 mRNA expression in NB4 cells at
day 4 and 6 of differentiation, respectively. Similarly, HT93 APL
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Fig. 3. Knocking down SENP5 attenuates neutrophil differentiation and survival of NB4 APL cells. (A) NB4 cells were stably transduced with non-targeting shRNA (SHC002)
or shRNAs targeting SENP5 (shSENP5_300 or shSENP5_1325) and differentiated with 1 μM ATRA for 4 days. SENP5 mRNA levels were quantiﬁed by qPCR and analyzed as in
(2A). (B) CEBPE qPCR of control and SENP5 knockdown cells treated as in (A). (C) CD11b ﬂow cytometric analysis of NB4 control (SHC002) and SENP5 knockdown cells. The
values are shown as median ﬂuorescence intensity (MFI) of CD11b expression normalized to the control. (D) alamarBlue cell viability assay of NB4 control and SENP5
knockdown cells at day 6 of ATRA treatment. Values were normalized to the respective untreated control ﬁrst, and then to the SHC002 stimulated control. Mann–Whitney-U
tests: npo0.05, nnpo0.01.
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cells displayed a 1.6- and 2.6-fold increase of SENP5 message at
day 4 and 6, respectively. Extending our analysis to HL60 cells, we
showed that increased SENP5 mRNA expression during neutrophil
differentiation is not APL speciﬁc (Fig. 2A, upper panels). Success-
ful neutrophil differentiation was monitored at day 4 and 6 by
CD11b cell surface expression (not shown) and by CEBPE mRNA
expression with qPCR (Fig. 2A, lower panels). In order to exclude
that upregulation of SENP5 was due to an ATRA-induced unspeciﬁc
stress response, we repeated the differentiation experiments in
ATRA-resistant NB4-R2 cells, which do not respond to ATRA
treatment. No signiﬁcant increase of SENP5 mRNA expression
was observed in these cells (Fig. 2A, left panel). Linking our
in vitro data to primary patient samples, we found that SENP5
mRNA levels were increased up to 2.4- and 6-fold in two APL
patients receiving oral ATRA and analyzed after short-term follow
up (Fig. 2B). Our results clearly point to a role for SENP5 during
neutrophil differentiation of APL as well as non-APL cells.
3.3. Knocking down SENP5 signiﬁcantly attenuates neutrophil
differentiation and survival of NB4 APL cells
Next, we evaluated whether SENP5 is functionally involved in
neutrophil differentiation of AML cells. Stable NB4 SENP5 knockdown
cell lines were generated using two different lentivirally delivered
small hairpin (sh) RNAs targeting SENP5. SENP5 downregulation was
conﬁrmed by qPCR (Fig. 3A). The neutrophil differentiation marker
CEBPE displayed 20–50% decreased expression in the different NB4
SENP5 knockdown cells upon ATRA-induced differentiation as com-
pared to control cells (Fig. 3B). We next conﬁrmed the effect of SENP5
inhibition on granulocyte differentiation using a second marker,
CD11b: NB4 SENP5 knockdown cell lines showed a 56%
(shSENP5_300) and 81% (shSENP5_1325) decrease in CD11b expres-
sion as compared to control cells (Fig. 3C). Interestingly, downregula-
tion of SENP5 mRNA in AML cell lines also resulted in signiﬁcantly
reduced cell viability upon differentiation (Fig. 3D).
Overall, inhibition of SENP5 expression in AML cell lines resulted
in signiﬁcantly reduced neutrophil differentiation and cell viability
upon ATRA treatment as compared to control cells. To our knowl-
edge, this is the ﬁrst study to investigate SENP5 regulation in primary
acute myeloid leukemias and primary healthy myeloid cells. First, we
found that SENP5mRNA expression is signiﬁcantly downregulated in
primary AML as compared to healthy neutrophils. Second, low SENP5
mRNA levels were associated with an immature myeloid phenotype
as evidenced by increased transcript levels of this gene during ATRA-
treatment of AML cell lines and APL patients. Importantly, knocking
down SENP5 in an APL neutrophil differentiation model resulted in
signiﬁcantly attenuated granulocyte differentiation and cell viability.
The low SENP5 expression seen in AML cells may promote increased
SUMOylation of proteins involved in cellular differentiation and cell
survival, thus potentially contributing to the myeloid differentiation
block. It has been reported that the nuclear form of SENP5 co-
localizes with the promyelocytic leukemia protein (PML), a key
player in leukemogenesis, possibly altering a variety of biological
functions [10]. We propose that additional studies may identify the
mechanisms by which this SUMO protease contributes to myeloid
differentiation.
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